1 Ruan, Q., Yang, K., Wang, W., Jiang, L. & Song, J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med, 1-3, doi:10.1007/s00134-020-05991-x (2020).
2 Maude, S. L., Barrett, D., Teachey, D. T. & Grupp, S. A. Managing cytokine release syndrome associated with novel T cell-engaging therapies. Cancer J 20, 119-122, doi:10.1097/PPO.0000000000000035 (2014).
3 Xu, Z. et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med 8, 420-422, doi:10.1016/S2213-2600(20)30076-X (2020).
4 Price, C. C. et al. Tocilizumab treatment for Cytokine Release Syndrome in hospitalized COVID-19 patients: survival and clinical outcomes. Chest, doi:10.1016/j.chest.2020.06.006 (2020).
5 Luo, P. et al. Tocilizumab treatment in COVID-19: A single center experience. J Med Virol 92, 814-818, doi:10.1002/jmv.25801 (2020).
6 Teachey, D. T. et al. Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia. Cancer discovery 6, 664-679, doi:10.1158/2159-8290.CD-16-0040 (2016).
7 Grupp, S. A. et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 368, 1509-1518, doi:10.1056/NEJMoa1215134 (2013).
8 Colaneri, M. et al. Tocilizumab for Treatment of Severe COVID-19 Patients: Preliminary Results from SMAtteo COvid19 REgistry (SMACORE). Microorganisms 8, doi:10.3390/microorganisms8050695 (2020).
9 Velazquez-Salinas, L., Verdugo-Rodriguez, A., Rodriguez, L. L. & Borca, M. V. The Role of Interleukin 6 During Viral Infections. Front Microbiol 10, 1057, doi:10.3389/fmicb.2019.01057 (2019).
10 Wu, W. et al. TLR ligand induced IL-6 counter-regulates the anti-viral CD8(+) T cell response during an acute retrovirus infection. Scientific reports 5, 10501, doi:10.1038/srep10501 (2015).
11 Hay, K. A. et al. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. Blood 130, 2295-2306, doi:10.1182/blood-2017-06-793141 (2017).
12 Campochiaro, C. et al. Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study. Eur J Intern Med 76, 43-49, doi:10.1016/j.ejim.2020.05.021 (2020).